Do you want to read an article? Please log in or register.
Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors
Lung Cancer
Related content
Lung Cancer
Real-World Creatinine-Based Estimates of Acute and Chronic Kidney Dysfunction in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
Clin Lung Cancer
Pinard L, Ullur AR, Everest L, Zhan LJ, Selvaratnam R, Balaratnam K, Khan K, Schmid S, Chotai S, Patel D, Al-Agha F, Grant B, Brown MC, Raptis R, Xu W, Moriarty P, Shepherd FA, Sacher AG, Leighl NB, Bradbury PA, Liu G, Kitchlu A
doi: 10.1016/j.cllc.2025.04.001
Lung Cancer
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors
Clin Lung Cancer
Bodor JN, Dowell J, Treat J, Subramanian J, Abdulla N, Lee E, Sankhala K, Lee CH, Makimoto G, Miyauchi E, Konduri K, Asahina H, Murakami S, Wen YF, Luo YH, Chang SY, Ewesuedo R, Zhou J, Goto Y
doi: 10.1016/j.cllc.2025.05.013
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
Clin Lung Cancer
Fortman D, Wang H, VanderWeele R, Evans T, Herman JG, Rhee J, Reyes V, McLaughlin B, Wozniak A, Somasundaram A, Mekhail T, Socinski MA, Schulze K, Villaruz LC
doi: 10.1016/j.cllc.2024.10.014
Lung Cancer
Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1-Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Peruzzo N, Lenz G, Akhiwu T, Bilalaga M, Gaddipati GN, Müller NLF, Zarpellon L, Venero F, Corassa M, Cardona AF, Reuss JE, Pellini B
doi: 10.1016/j.cllc.2025.04.006
Lung Cancer
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer
Clin Lung Cancer
Vakkalagadda CV, Bucheit L, Clemens K, Saha J, Zhang N, Patel JD
doi: 10.1016/j.cllc.2025.07.007
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
Lung Cancer
The prognostic significance of diabetes in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
Diabetes Res Clin Pract
Nguyen NN, Ha Nguyen TH, Hoang KD, Vo TK, Minh Pham QH, Chen YC
doi: 10.1016/j.diabres.2024.111930